Skip to main content
Inflammatory Bowel Diseases logoLink to Inflammatory Bowel Diseases
. 2021 Jan 29;27(7):1175. doi: 10.1093/ibd/izab014

Corrigendum to: Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

PMCID: PMC8205630  PMID: 33511983

Under the “Major Adverse Cardiovascular Events and Deep Vein Thrombosis/Pulmonary Embolism” heading, the frist sentence should read: “Incidence of adjudicated serious MACE per 100 PYs was low through 1 year, with 2 patients each in the placebo- (0.34) and ustekinumab-treated (0.12) pooled IBD population (Table 3).” instead of “Incidence of adjudicated serious MACE per 100 PYs was low through 1 year, with 1 patient each in the placebo- (0.34) and ustekinumab-treated (0.12) pooled IBD population (Table 4).”

In Figure 1, the y-axis should be corrected by deleting “per 100 patient-years” to read: “Number of events.” Figure 1 has been updated as follows:

graphic file with name izab014_iffig1.jpg


Articles from Inflammatory Bowel Diseases are provided here courtesy of Oxford University Press

RESOURCES